Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF4TRANS: F/TAF PrEP Switch in Transgender Individuals
NCT04616963Phase 4Active, not recruiting
- Sponsor
- University of California, San Diego
- Start
- Oct 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by University of California, San Diego. Started Oct 2019; status: active, not recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04616963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616963.